AbCellera Biologics appointed Dr. Lynn Seely as a new Class III director on June 30, 2026. Her term runs through the 2029 annual shareholder meeting. She meets Nasdaq's independence standards and will follow the standard non-employee director compensation plan. She currently has no board committee assignments and no material ties to the company.

View Full Filing (SEC EDGAR)

View all Form 8-K filings

FAQ

Who are the top institutional investors holding ABCELLERA BIOLOGICS INC (ABCL)?

Major stakeholders currently include Baker Bros. Advisors LP ($105.7M), Capital World Investors ($46.6M), Two Sigma Investments, LP ($36.9M). Based on the latest 13F filings, there are a total of 137 tracked investment funds and institutions maintaining positions in ABCL.

What is the overall institutional sentiment toward ABCL recently?

Institutional sentiment appears Bullish (Net Buying). During the most recent reporting quarter, the stock experienced a net inflow of $75.2M, driven by 73 managers accumulating shares while 62 reduced their exposure.

Which institutions have been selling or reducing their ABCL positions?

In the latest period, 35 funds trimmed their holdings, and 27 managers completely exited their positions. The aggregate reported sell value was $126.3M.

Are there any notable investors adding ABCL to their portfolios?

Yes, buying activity remains notable. 18 institutions opened new positions in {ticker}, and 55 existing holders added to their shares. The total reported buy value for the quarter amounted to $299.3M.